uniQure (QURE) Stock Forecast, Price Target & Predictions
QURE Stock Forecast
uniQure stock forecast is as follows: an average price target of $53.67 (represents a 848.23% upside from QURE’s last price of $5.66) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
QURE Price Target
The average price target for uniQure (QURE) is $53.67 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $62.00 to $34.00. This represents a potential 848.23% upside from QURE's last price of $5.66.
QURE Analyst Ratings
According to 7 Wall Street analysts, uniQure's rating consensus is 'Buy'. The analyst rating breakdown for QURE stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
uniQure Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 23, 2022 | - | Goldman Sachs | $57.00 | $25.38 | 124.59% | 907.07% |
| Aug 08, 2022 | Matthew Barcus | Chardan Capital | $60.00 | $18.64 | 221.89% | 960.07% |
| May 03, 2022 | - | Credit Suisse | $51.00 | $15.85 | 221.77% | 801.06% |
| Jan 07, 2022 | Yanan Zhu | Wells Fargo | $34.00 | $19.50 | 74.36% | 500.71% |
| Dec 16, 2021 | Danielle Brill | Raymond James | $58.00 | $20.24 | 186.56% | 924.73% |
| Oct 28, 2021 | Suji Jeong | Jefferies | $62.00 | $30.65 | 102.28% | 995.41% |
The latest uniQure stock forecast, released on Nov 23, 2022 by Goldman Sachs company, set a price target of $57.00, which represents a 124.59% increase from the stock price at the time of the forecast ($25.38), and a 907.07% increase from QURE last price ($5.66).
uniQure Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.66 | $5.66 | $5.66 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of uniQure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to uniQure's last price of $5.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 09, 2024 | Guggenheim | Buy | Buy | Hold |
| Mar 04, 2024 | Cowen & Co. | Neutral | Neutral | Hold |
| Jun 22, 2023 | Chardan Capital | Buy | Buy | Hold |
| Feb 28, 2023 | Credit Suisse | Outperform | Outperform | Hold |
| Dec 29, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 23, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 03, 2022 | SVB Leerink | Outperform | Outperform | Hold |
uniQure's last stock rating was published by Guggenheim on Jul 09, 2024. The company gave QURE a "Buy" rating, the same as its previous rate.
uniQure Financial Forecast
uniQure Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.41M | - | $5.33M | $102.75M | $1.45M | - | $1.79M | $57.69M | $1.99M | $463.87M | $454.00K | $34.09M | $1.79M | $1.53M | $104.00K | $2.63M | $1.05M |
| Avg Forecast | $7.13M | $7.13M | $7.13M | $7.13M | $31.51M | $10.47M | $8.82M | $32.82M | $17.68M | $7.14M | $6.84M | $6.29M | $5.60M | $29.49M | $166.71M | $28.25M | $19.42M | $3.48M | $10.19M | $17.66M | $10.75M | $2.52M | $190.02M | $2.27M | $120.05M | $133.27M | $5.12M | $1.34M | $1.51M | $2.31M |
| High Forecast | $7.13M | $7.13M | $7.13M | $7.13M | $31.51M | $10.47M | $8.82M | $32.82M | $17.68M | $14.35M | $6.84M | $6.29M | $8.75M | $29.49M | $166.71M | $28.25M | $19.42M | $3.48M | $10.19M | $35.54M | $21.63M | $5.07M | $382.39M | $4.56M | $241.59M | $268.20M | $10.30M | $2.69M | $3.04M | $4.64M |
| Low Forecast | $7.13M | $7.13M | $7.13M | $7.13M | $31.51M | $10.47M | $8.82M | $32.82M | $17.68M | $3.38M | $6.84M | $6.29M | $1.23M | $29.49M | $166.71M | $28.25M | $19.42M | $3.48M | $10.19M | $6.56M | $3.99M | $935.10K | $70.59M | $841.60K | $44.60M | $49.51M | $1.90M | $497.44K | $561.28K | $857.24K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | - | 0.19% | 5.29% | 0.42% | - | 0.10% | 5.37% | 0.79% | 2.44% | 0.20% | 0.28% | 0.01% | 0.30% | 0.08% | 1.74% | 0.45% |
uniQure's average Quarter revenue forecast for Dec 23 based on 8 analysts is $5.60M, with a low forecast of $1.23M, and a high forecast of $8.75M. QURE's average Quarter revenue forecast represents a 298.09% increase compared to the company's last Quarter revenue of $1.41M (Sep 23).
uniQure EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-81.88M | - | $-69.98M | $28.69M | $-57.38M | - | $-51.22M | $11.81M | $-32.74M | $406.43M | $-37.93M | $2.53M | $-47.98M | $-39.81M | $-25.29M | $-38.73M | $-20.93M |
| Avg Forecast | $-4.84M | $-4.84M | $-4.84M | $-4.84M | $-21.38M | $-7.10M | $-5.99M | $-22.28M | $-12.00M | $-4.85M | $-4.64M | $-34.48M | $-3.80M | $-20.01M | $-113.14M | $-36.88M | $-13.18M | $-76.86M | $-6.91M | $-39.45M | $-7.29M | $-82.21M | $-128.96M | $-36.64M | $-81.47M | $-115.24M | $-24.84M | $-31.61M | $-1.03M | $-26.87M |
| High Forecast | $-4.84M | $-4.84M | $-4.84M | $-4.84M | $-21.38M | $-7.10M | $-5.99M | $-22.28M | $-12.00M | $-2.29M | $-4.64M | $-27.59M | $-831.51K | $-20.01M | $-113.14M | $-29.51M | $-13.18M | $-61.49M | $-6.91M | $-31.56M | $-2.71M | $-65.76M | $-47.91M | $-29.31M | $-30.27M | $-92.19M | $-19.87M | $-25.29M | $-380.91K | $-21.50M |
| Low Forecast | $-4.84M | $-4.84M | $-4.84M | $-4.84M | $-21.38M | $-7.10M | $-5.99M | $-22.28M | $-12.00M | $-9.74M | $-4.64M | $-41.38M | $-5.94M | $-20.01M | $-113.14M | $-44.26M | $-13.18M | $-92.23M | $-6.91M | $-47.34M | $-14.68M | $-98.65M | $-259.51M | $-43.96M | $-163.96M | $-138.29M | $-29.80M | $-37.94M | $-2.06M | $-32.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.09% | - | 1.90% | -2.18% | 0.75% | - | 1.30% | -1.62% | 0.40% | -3.15% | 1.04% | -0.03% | 0.42% | 1.60% | 0.80% | 37.78% | 0.78% |
4 analysts predict QURE's average Quarter EBITDA for Mar 23 to be $-36.88M, with a high of $-29.51M and a low of $-44.26M. This is -228.56% lower than uniQure's previous annual EBITDA (Dec 22) of $28.69M.
uniQure Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-89.57M | - | $-77.23M | $6.81M | $-47.86M | - | $-46.68M | $8.21M | $-36.53M | $399.47M | $-41.56M | $-699.00K | $-53.77M | $-42.55M | $-28.00M | $-41.43M | $-23.60M |
| Avg Forecast | $-48.20M | $-46.14M | $-43.02M | $-41.93M | $-20.02M | $-37.81M | $-43.39M | $-23.29M | $-39.47M | $-49.26M | $-60.93M | $-37.74M | $-70.75M | $-41.55M | $114.92M | $-40.36M | $-43.11M | $-85.77M | $-48.19M | $-43.16M | $16.42M | $-91.73M | $393.86M | $-40.14M | $-40.78M | $-129.15M | $-26.55M | $-35.00M | $-34.20M | $-30.31M |
| High Forecast | $-48.20M | $-46.14M | $-43.02M | $-41.93M | $-20.02M | $-37.81M | $-43.39M | $-23.29M | $-39.47M | $-42.66M | $-60.93M | $-30.19M | $-55.13M | $-41.55M | $114.92M | $-32.29M | $-43.11M | $-68.61M | $-48.19M | $-34.53M | $19.70M | $-73.38M | $472.63M | $-32.11M | $-7.46M | $-103.32M | $-21.24M | $-28.00M | $-6.26M | $-24.25M |
| Low Forecast | $-48.20M | $-46.14M | $-43.02M | $-41.93M | $-20.02M | $-37.81M | $-43.39M | $-23.29M | $-39.47M | $-58.06M | $-60.93M | $-45.28M | $-86.83M | $-41.55M | $114.92M | $-48.43M | $-43.11M | $-102.92M | $-48.19M | $-51.80M | $13.13M | $-110.08M | $315.09M | $-48.17M | $-94.45M | $-154.98M | $-31.86M | $-42.00M | $-79.21M | $-36.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.16% | - | 1.91% | -0.16% | 0.56% | - | 1.08% | 0.50% | 0.40% | 1.01% | 1.04% | 0.02% | 0.42% | 1.60% | 0.80% | 1.21% | 0.78% |
uniQure's average Quarter net income forecast for Mar 23 is $-40.36M, with a range of $-48.43M to $-32.29M. QURE's average Quarter net income forecast represents a -692.90% decrease compared to the company's last Quarter net income of $6.81M (Dec 22).
uniQure SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $18.07M | - | $17.85M | $18.26M | $13.32M | - | $10.99M | $13.97M | $12.02M | $17.30M | $12.38M | $11.21M | $10.79M | $11.51M | $9.07M | $8.68M | $8.93M |
| Avg Forecast | $15.80M | $15.80M | $15.80M | $15.80M | $69.79M | $23.18M | $19.54M | $72.70M | $39.17M | $15.82M | $15.15M | $13.93M | $12.41M | $65.31M | $369.26M | $9.50M | $43.01M | $7.72M | $22.56M | $10.16M | $23.80M | $5.57M | $17.06M | $5.02M | $265.91M | $25.91M | $11.34M | $2.97M | $3.35M | $5.11M |
| High Forecast | $15.80M | $15.80M | $15.80M | $15.80M | $69.79M | $23.18M | $19.54M | $72.70M | $39.17M | $31.79M | $15.15M | $13.93M | $19.38M | $65.31M | $369.26M | $11.40M | $43.01M | $7.72M | $22.56M | $12.19M | $47.90M | $11.22M | $20.47M | $10.10M | $535.11M | $31.09M | $22.82M | $5.97M | $6.73M | $10.28M |
| Low Forecast | $15.80M | $15.80M | $15.80M | $15.80M | $69.79M | $23.18M | $19.54M | $72.70M | $39.17M | $7.48M | $15.15M | $13.93M | $2.71M | $65.31M | $369.26M | $7.60M | $43.01M | $7.72M | $22.56M | $8.13M | $8.84M | $2.07M | $13.64M | $1.86M | $98.79M | $20.73M | $4.21M | $1.10M | $1.24M | $1.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.28% | - | 1.88% | 0.42% | 1.73% | - | 1.08% | 0.59% | 2.16% | 1.01% | 2.47% | 0.04% | 0.42% | 1.02% | 3.06% | 2.59% | 1.75% |
uniQure's average Quarter SG&A projection for Dec 23 is $12.41M, based on 8 Wall Street analysts, with a range of $2.71M to $19.38M. The forecast indicates a -31.36% fall compared to QURE last annual SG&A of $18.07M (Sep 23).
uniQure EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.88 | - | $-1.63 | $0.15 | $-1.02 | - | $-1.00 | $0.18 | $-0.79 | $8.68 | $-0.91 | $-0.02 | $-1.21 | $-0.96 | $-0.63 | $-1.04 | $-0.58 |
| Avg Forecast | $-0.99 | $-0.95 | $-0.88 | $-0.86 | $-0.41 | $-0.78 | $-0.89 | $-0.48 | $-0.81 | $-1.01 | $-1.25 | $-1.28 | $-1.46 | $-0.85 | $2.36 | $-0.95 | $-0.89 | $-1.20 | $-1.00 | $-0.93 | $-0.82 | $-1.05 | $2.97 | $-0.89 | $-0.85 | $1.99 | $-0.65 | $-0.72 | $-0.71 | $-0.81 |
| High Forecast | $-0.99 | $-0.95 | $-0.88 | $-0.86 | $-0.41 | $-0.78 | $-0.89 | $-0.48 | $-0.81 | $-0.88 | $-1.25 | $-1.28 | $-1.13 | $-0.85 | $2.36 | $-0.95 | $-0.89 | $-1.20 | $-1.00 | $-0.17 | $-0.15 | $-0.19 | $6.88 | $-0.16 | $-0.16 | $4.60 | $-0.12 | $-0.13 | $-0.13 | $-0.15 |
| Low Forecast | $-0.99 | $-0.95 | $-0.88 | $-0.86 | $-0.41 | $-0.78 | $-0.89 | $-0.48 | $-0.81 | $-1.19 | $-1.25 | $-1.28 | $-1.79 | $-0.85 | $2.36 | $-0.95 | $-0.89 | $-1.20 | $-1.00 | $-2.16 | $-1.90 | $-2.43 | $0.54 | $-2.07 | $-1.97 | $0.36 | $-1.51 | $-1.67 | $-1.66 | $-1.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20% | - | 1.72% | -0.17% | 0.85% | - | 1.07% | -0.22% | 0.75% | 2.92% | 1.02% | 0.02% | -0.61% | 1.48% | 0.87% | 1.45% | 0.72% |
According to 4 Wall Street analysts, uniQure's projected average Quarter EPS for Mar 23 is $-0.95, with a low estimate of $-0.95 and a high estimate of $-0.95. This represents a -731.49% decrease compared to QURE previous annual EPS of $0.15 (Dec 22).
uniQure Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| QURE | uniQure | $5.66 | $53.67 | 848.23% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| RGNX | REGENXBIO | $12.84 | $38.00 | 195.95% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| RCKT | Rocket Pharmaceuticals | $19.65 | $47.33 | 140.87% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| SLDB | Solid Biosciences | $7.93 | $17.50 | 120.68% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
| PHAT | Phathom Pharmaceuticals | $18.30 | $25.83 | 41.15% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
QURE Forecast FAQ
Is uniQure a good buy?
Yes, according to 7 Wall Street analysts, uniQure (QURE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of QURE's total ratings.
What is QURE's price target?
uniQure (QURE) average price target is $53.67 with a range of $34 to $62, implying a 848.23% from its last price of $5.66. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will uniQure stock go up soon?
According to Wall Street analysts' prediction for QURE stock, the company can go up by 848.23% (from the last price of $5.66 to the average price target of $53.67), up by 995.41% based on the highest stock price target, and up by 500.71% based on the lowest stock price target.
Can uniQure stock reach $8?
QURE's average twelve months analyst stock price target of $53.67 supports the claim that uniQure can reach $8 in the near future.
What are uniQure's analysts' financial forecasts?
uniQure's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $83.62M (high $83.62M, low $83.62M), average EBITDA is $-56.748M (high $-56.748M, low $-56.748M), average net income is $-125M (high $-125M, low $-125M), average SG&A $185.21M (high $185.21M, low $185.21M), and average EPS is $-2.561 (high $-2.561, low $-2.561). QURE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $28.53M (high $28.53M, low $28.53M), average EBITDA is $-19.363M (high $-19.363M, low $-19.363M), average net income is $-179M (high $-179M, low $-179M), average SG&A $63.2M (high $63.2M, low $63.2M), and average EPS is $-3.687 (high $-3.687, low $-3.687).
Did the QURE's actual financial results beat the analysts' financial forecasts?
Based on uniQure's last annual report (Dec 2023), the company's revenue was $15.84M, which missed the average analysts forecast of $230.05M by -93.11%. Apple's EBITDA was $-283M, beating the average prediction of $-174M by 62.72%. The company's net income was $-308M, beating the average estimation of $-37.742M by 717.34%. Apple's SG&A was $74.59M, missing the average forecast of $456.48M by -83.66%. Lastly, the company's EPS was $-0.0065, missing the average prediction of $-0.893 by -99.27%. In terms of the last quarterly report (Sep 2023), uniQure's revenue was $1.41M, missing the average analysts' forecast of $29.49M by -95.23%. The company's EBITDA was $-81.877M, beating the average prediction of $-20.012M by 309.13%. uniQure's net income was $-89.571M, beating the average estimation of $-41.55M by 115.57%. The company's SG&A was $18.07M, missing the average forecast of $65.31M by -72.33%. Lastly, the company's EPS was $-1.88, beating the average prediction of $-0.855 by 120.00%